文献速递临床试验与 GCP流行病学与生物统计

维生素D补充与安慰剂对COVID-19突尼斯患者康复延迟影响的随机对照临床试验

Effect of vitamin D supplementation versus placebo on recovery delay among COVID-19 Tunisian patients: a randomized-controlled clinical trial.
PubMed 文献 · Trials · 2023-02-20

该随机对照试验在突尼斯莫纳斯提尔的国家COVID-19收治中心纳入117例第14天RT-PCR仍阳性的COVID-19患者,干预组接受胆钙化醇200,000 IU/1 ml,对照组接受生理盐水1 ml安慰剂。干预组病毒RNA转阴中位时间37天(95%CI:29-45.50) vs 安慰剂组28天(95%CI:23-39),p=0.010,HR为1.58(95%CI:1.09-2.29,p=0.015);两组Ct值随时间呈稳定趋势。结论认为维生素D补充未与缩短康复延迟相关。

要点

  • 干预组病毒RNA转阴中位时间37天 vs 安慰剂组28天(p=0.010),HR为1.58(95%CI:1.09-2.29)。
  • 两组Ct值随时间呈稳定趋势。
  • 结论认为维生素D补充未与缩短康复延迟相关。

核心结论

  • 维生素D补充用于第14天RT-PCR仍阳性的患者时,未与缩短康复延迟相关。

研究设计与样本

  • 在突尼斯莫纳斯提尔国家COVID-19收治中心开展的随机对照临床试验,2020年5月至8月进行,按1:1比例简单随机化。
  • 纳入年龄大于18岁、RT-PCR确诊且第14天仍阳性的患者,共117例;干预组接受胆钙化醇200,000 IU/1 ml,对照组接受生理盐水1 ml安慰剂。
  • 测量康复延迟和SARS-CoV-2 RT-PCR的Ct值,计算log-rank检验和风险比(HR)。

主要发现

  • 患者平均年龄42.7岁(SD 14),男性占55.6%。
  • 干预组病毒RNA转阴中位时间37天(95%CI:29-45.50) vs 安慰剂组28天(95%CI:23-39),p=0.010。
  • HR为1.58(95%CI:1.09-2.29,p=0.015)。
  • 两组Ct值随时间呈稳定趋势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The present study aimed to determine the impact of vitamin D supplementation (VDs) on recovery delay among COVID-19 patients. METHODS: We performed a randomized controlled clinical trial at the national COVID-19 containment center in Monastir (Tunisia), from May to August 2020. Simple randomization was done in a 1:1 allocation ratio. We included patients aged more than 18 years who had confirmed reverse transcription-polymerase chain reaction (RT-PCR) and who remained positive on the 14th day. The intervention group received VDs (200,000 IU/1 ml of cholecalciferol); the control group received a placebo treatment (physiological saline (1 ml)). We measured the recovery delay and the cycle threshold (Ct) values in RT-PCR for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The log-rank test and hazard ratios (HR) were calculated. RESULTS: A total of 117 patients were enrolled. The mean age was 42.7 years (SD 14). Males represented 55.6%. The median duration of viral RNA conversion was 37 days (95% confidence interval (CI): 29-45.50) in the intervention group and 28 days (95% CI: 23-39) in the placebo group (p=0.010). HR was 1.58 (95% CI: 1.09-2.29, p=0.015). Ct values revealed a stable trend over time in both groups. CONCLUSION: VDs was not associated with a shortened recovery delay when given to patients for whom the RT-PCR remained positive on the 14th day. TRIAL REGISTRATION: This study was approved by the Human Subjects Protection Tunisia center (TN2020-NAT-INS-40) on April 28, 2020, and by ClinicalTrial.gov on May 12, 2021 with approval number ClinicalTrials.gov ID: NCT04883203 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Abroug H, Maatouk A, Bennasrallah C, et al. Effect of vitamin D supplementation versus placebo on recovery delay among COVID-19 Tunisian patients: a randomized-controlled clinical trial. Trials. 2023. PMID: 36803273. doi:10.1186/s13063-023-07114-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。